Tharimmune, Inc. Announces $55 Million Public Offering to Boost Digital Transition

Tharimmune, Inc. Schedules $55 Million Stock Offering

NEW YORK, January 20, 2026 – Tharimmune, Inc. (NASDAQ: THAR), a pioneering firm that is the first publicly traded entity to utilize Canton Coin, has made headlines with its recent announcement regarding a registered public offering valued at $55 million. This significant move not only reinforces the company's position within the cryptocurrency space but also aims to facilitate the digitization of traditional financial markets through the Canton Network, known for its secure and privacy-centric blockchain technology.

Canton Network is a vital platform that hosts digital assets worth trillions, which provides Tharimmune with a unique opportunity to operate a differentiated digital asset treasury strategy. As blockchain adoption surges in institutional finance, Tharimmune plans to leverage its offerings to expand its market influence and operational capability.

The offering is slated for closure around January 21, 2026, pending the usual conditions that must be fulfilled. The company is set to issue 1,800,000 shares of common stock at a price of $2.92 per share, along with pre-funded warrants allowing purchasers to buy up to 17,000,000 additional shares at a slight premium of $2.9199 per warrant. This capital infusion will bolster the company's expansion efforts and provide necessary working capital for general corporate purposes.

Strategic Growth and Expansion Potential
Clear Street has been designated as the sole bookrunner orchestrating this offering, efficiently managing the company's financial operations for maximum growth potential. The securities being offered are part of a shelf registration statement filed with the Securities and Exchange Commission (SEC) earlier this month, which became effective shortly thereafter. Documents regarding the offering can be accessed through the SEC's website or by contacting Clear Street directly.

This public offering stands as a clear signal of Tharimmune's commitment to advancing its Canton-centric digital asset treasury strategy while also maintaining its robustness in clinical-stage biotech research and development. Such a dual focus on digital assets and biopharmaceuticals positions Tharimmune uniquely within emerging technology sectors.

Investors are encouraged to understand the associated risks outlined in the company's filings with the SEC, including its annual report which addresses critical risk factors. Tharimmune candidly states that while they project strategic growth and market integration, actual results may vary significantly due to various market uncertainties and conditions.

About Tharimmune, Inc.
As a trailblazer in the blockchain realm, Tharimmune has firmly established itself as a leader in digital asset treasury management through its engagement with the Canton Network. Their overarching objective centers on enhancing institutional adoption of blockchain technologies, thereby revolutionizing how traditional financial systems operate and interact. For further insights and updates, interested parties can visit their website at www.tharimmune.com.

Tharimmune remains steadfast in its mission, navigating a landscape fraught with challenges but equally ripe with opportunities. As the future unfolds, the company's strategies underway promise to unlock substantial value for its stakeholders and redefine norms in the digital asset frontier.